Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Myriad Genetics, Inc. - Common Stock (NQ:MYGN)

5.540 +1.330 (+31.59%)
Delayed Quote Updated: 4:00 PM EDT, Oct 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Myriad Genetics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Top US Stock Movers: Today's Session Gainers and Losers ↗
Via Chartmill
Top Movers: Gainers Rise 55.88%, Losers Fall 53.13% in Today's Session ↗
Via Chartmill
Gap Stocks: Gap-Up and Gap-Down Movers in Today's Session ↗
Via Chartmill
News headline image
Myriad Genetics (MYGN) Stock Trades Up, Here Is Why
What Happened? Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) jumped 22.2% in the pre-market session after the company agreed to sell its Pr... 
Via StockStory
Topics Artificial Intelligence
News headline image
Myriad Genetics and Labcorp Announce Definitive Agreement for Myriad to Sell Prenatal Health Testing Business to Labcorp
Transaction to benefit patients through expanded access and support Myriad’s strategic priorities 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
2 Small-Cap Stocks to Consider Right Now and 1 We Turn Down
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and... 
Via StockStory
News headline image
Azenta, Myriad Genetics, Moderna, Repligen, and PacBio Shares Plummet, What You Need To Know
What Happened? A number of stocks fell in the afternoon session after capital-intensive growth equities experienced sharp sell-offs as elevated bond yields r... 
Via StockStory
Topics Bonds Economy
News headline image
Myriad Genetics to Release Third Quarter 2026 Financial Results on November 4, 2026
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Q2 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the biotechnology industry, including Regeneron (NASDAQ:REGN) and... 
Via StockStory
Topics Artificial Intelligence
News headline image
Myriad Genetics and SOPHiA GENETICS Announce New Collaboration to Advance Prostate Genomic Instability Score Technology
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Therapeutics Stocks Q2 Highlights: Gilead Sciences (NASDAQ:GILD)
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Gilead Sciences (NASDAQ:GILD)... 
Via StockStory
Topics Artificial Intelligence
News headline image
Why Is Myriad Genetics (MYGN) Stock Soaring Today
What Happened? Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) jumped 5% in the afternoon session after Craig-Hallum analyst John Wilkin rais... 
Via StockStory
News headline image
1 Volatile Stock on Our Buy List and 2 We Question
A highly volatile stock can deliver big gains - or just as easily wipe out a portfolio if things go south. While some investors embrace risk, mistakes can be... 
Via StockStory
News headline image
3 Reasons MYGN is Risky and 1 Stock to Buy Instead
Over the past six months, Myriad Genetics’s stock price fell to $4.01. Shareholders have lost 13% of their capital, which is disappointing considering the S&... 
Via StockStory
Topics Bankruptcy
News headline image
Reflecting On Therapeutics Stocks’ Q2 Earnings: AbbVie (NYSE:ABBV)
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at AbbVie (NYSE:ABBV) and its pe... 
Via StockStory
Topics Artificial Intelligence
News headline image
1 Unpopular Stock That Deserves Some Love and 2 We Turn Down
When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fea... 
Via StockStory
News headline image
Myriad Genetics Appoints Vishal Sikri Executive Vice President - Commercial
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
2 Unprofitable Stocks to Research Further and 1 We Find Risky
Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, th... 
Via StockStory
News headline image
Q2 Rundown: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs Other Therapeutics Stocks
As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including Vertex Pharmaceuticals (NASD... 
Via StockStory
Topics Artificial Intelligence
News headline image
Therapeutics Stocks Q2 Recap: Benchmarking Myriad Genetics (NASDAQ:MYGN)
Wrapping up Q2 earnings, we look at the numbers and key takeaways for the therapeutics stocks, including Myriad Genetics (NASDAQ:MYGN) and its peers. Over th... 
Via StockStory
Topics Artificial Intelligence
News headline image
Stocks making big moves yesterday: Myriad Genetics, Greenbrier, Tidewater, Strategy, and Charter
Check out the companies making headlines yesterday: Myriad Genetics (NASDAQ:MYGN): Genetic testing company Myriad Genetics (NASDAQ:MYGN) fell by 6.2% on Tues... 
Via StockStory
Topics Economy
News headline image
Why Myriad Genetics (MYGN) Stock Is Down Today
What Happened? Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) fell 6.2% in the afternoon session after Piper Sandler double-downgraded the s... 
Via StockStory
News headline image
Q2 Earnings Highlights: Moderna (NASDAQ:MRNA) Vs The Rest Of The Therapeutics Stocks
Wrapping up Q2 earnings, we look at the numbers and key takeaways for the therapeutics stocks, including Moderna (NASDAQ:MRNA) and its peers. Over the next f... 
Via StockStory
Topics Artificial Intelligence
News headline image
Myriad Genetics to Present at 2026 Wells Fargo Healthcare Conference
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics and Moderna Shares Plummet, What You Need To Know
What Happened? A number of stocks fell in the afternoon session after shares across biotech and big pharma cooled further as traders continued to secure prof... 
Via StockStory
News headline image
1 Small-Cap Stock with Promising Prospects and 2 That Underwhelm
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that ... 
Via StockStory
Topics Artificial Intelligence
News headline image
Q2 Rundown: Natera (NASDAQ:NTRA) Vs Other Biotechnology Stocks
The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how biotechnology stocks f... 
Via StockStory
Topics Artificial Intelligence
News headline image
MYGN SHAREHOLDER ALERT: Myriad Genetics Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
From Kirby McInerney LLP
Via Business Wire
News headline image
3 Healthcare Stocks with Open Questions
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from eleva... 
Via StockStory
News headline image
MYGN Investors Have Opportunity to Join Myriad Genetics, Inc. Fraud Investigation with SBS Law
From Schall, Brown & Schwartz LLP
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback